Louisiana State Employees Retirement System Buys Shares of 41,700 The Chemours Company (NYSE:CC)

→ Gold Mania (From Stansberry Research) (Ad)

Louisiana State Employees Retirement System purchased a new position in shares of The Chemours Company (NYSE:CC - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 41,700 shares of the specialty chemicals company's stock, valued at approximately $1,315,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CC. Legacy Financial Group LLC acquired a new stake in shares of Chemours during the third quarter worth $29,000. Morton Brown Family Wealth LLC acquired a new stake in shares of Chemours during the fourth quarter worth $35,000. Anchor Investment Management LLC acquired a new stake in Chemours in the 4th quarter valued at $56,000. Geneos Wealth Management Inc. increased its stake in Chemours by 116.4% in the 4th quarter. Geneos Wealth Management Inc. now owns 1,859 shares of the specialty chemicals company's stock valued at $59,000 after buying an additional 1,000 shares during the last quarter. Finally, IFP Advisors Inc increased its stake in Chemours by 39.0% in the 3rd quarter. IFP Advisors Inc now owns 2,232 shares of the specialty chemicals company's stock valued at $63,000 after buying an additional 626 shares during the last quarter. 76.26% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on CC shares. BMO Capital Markets raised shares of Chemours from an "underperform" rating to an "outperform" rating and increased their price objective for the company from $19.00 to $34.00 in a research report on Tuesday, April 9th. UBS Group increased their price objective on shares of Chemours from $21.00 to $28.00 and gave the company a "neutral" rating in a research report on Tuesday, April 2nd. Finally, Barclays decreased their price target on shares of Chemours from $32.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 2nd. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $30.89.


View Our Latest Analysis on Chemours

Chemours Price Performance

Chemours stock traded up $0.51 during trading hours on Monday, reaching $26.42. 1,038,898 shares of the stock were exchanged, compared to its average volume of 1,882,393. The company has a market cap of $3.93 billion, a P/E ratio of -17.05 and a beta of 2.00. The company has a current ratio of 1.54, a quick ratio of 1.00 and a debt-to-equity ratio of 5.40. The Chemours Company has a twelve month low of $15.10 and a twelve month high of $39.05. The stock has a 50 day moving average of $26.80 and a two-hundred day moving average of $27.80.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The specialty chemicals company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.29 by $0.02. The firm had revenue of $1.36 billion for the quarter, compared to the consensus estimate of $1.37 billion. Chemours had a negative net margin of 3.80% and a positive return on equity of 51.73%. Equities analysts expect that The Chemours Company will post 2.23 EPS for the current fiscal year.

Chemours Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Monday, February 26th were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.00 dividend on an annualized basis and a yield of 3.79%. Chemours's payout ratio is -64.52%.

About Chemours

(Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

See Also

Institutional Ownership by Quarter for Chemours (NYSE:CC)

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Should you invest $1,000 in Chemours right now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Featured Articles and Offers

Search Headlines: